2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
9476
Neoplasms
6587
Prostatic Neoplasms
4399
Colorectal Neoplasms
3977
Lung Neoplasms
3642
Carcinoma, Non-Small-Cell Lung
3583
Pancreatic Neoplasms
2478
Carcinoma, Hepatocellular
2411
Leukemia, Myeloid, Acute
2265
Multiple Myeloma
2120
Stomach Neoplasms
2108
Neoplasm Metastasis
1911
Head and Neck Neoplasms
1869
Ovarian Neoplasms
1773
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1734
Lymphoma
1729
Brain Neoplasms
1699
Rectal Neoplasms
1676
Melanoma
1654
Colonic Neoplasms
1629
Leukemia
1500
Uterine Cervical Neoplasms
1499
Recurrence
1485
Esophageal Neoplasms
1311
Glioblastoma
1307
Lymphoma, Non-Hodgkin
1204
Leukemia, Lymphocytic, Chronic, B-Cell
1120
Squamous Cell Carcinoma of Head and Neck
1109
Urinary Bladder Neoplasms
1078
Lymphoma, Follicular
1067
Interventions
padeliporfin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Transitional Cell Cancer of Renal Pelvis and Ureter
×
Clear all
NCT04620239
2026-02-04
UCM301
Steba Biotech S.A.
Phase 3
Recruiting
100 enrolled